Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVIBiotechnology
-$0.15 today
- Market cap
- $2.10B
- Beta
- 0.71
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.71
Volume 1.41M
Average 2.42M
MRVI Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Maravai LifeSciences Holdings, Inc.NASDAQ: MRVI
Operating Income · Q2 FY2026 · quarter ended Jun 2026
Operating income remains negative
Q2 FY2026 operating income was -$15.09M, compared with -$66.28M a year earlier. Trailing-twelve-month operating income was $96.09M.
Context
- Operating income amounted to 3.6% of revenue in FY2025, down 87.3 pp from a year earlier.
- Operating income increased in 1 of the last 3 fiscal years.
What to watch
Whether operating income reaches the consensus estimate from 7 analysts of $29.89M (+543.6%) for the fiscal year ending Dec 2026, a step up from the +97.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$15.09M-709.9% QoQ
- Last fiscal yearDec 2025
- -$6.74M+97.1% YoY
- LTMJun 2026
- $96.09M+129.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +77.2% | -104.9% | -182.1 pp |
| 1 year | +97.1% | +543.6% | +446.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (6.74M) USD
- Year-over-year change
- +97.1%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (6.74M) | +97.1% |
| FY2024 | 2024-12-31 | (235.62M) | -644.5% |
| FY2023 | 2023-12-31 | (31.65M) | -105.5% |
| FY2022 | 2022-12-31 | 574.22M | +3.5% |
| FY2021 | 2021-12-31 | 554.65M | — |
Operating Income vs competitors
How MRVI compares with its peers on the latest reported figures
- MRVI's LTM Jun 2026 operating income of $96.09M is the 3rd highest of the 9 companies compared; the peer median is -$9.13M.
- Its year-over-year change of +129.8% is the 2nd highest of 9, against a peer median of +19.6%.
- Operating income amounts to 46.0% of revenue for MRVI, versus a peer median of 15.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $240.84M | +119.1% | -5.5% | 19.6% | |
| LTM Jun 2026 | $235M | +5.1% | -17.6% | 9.1% | |
| LTM Jun 2026 | $96.09M | +129.8% | — | 46.0% | |
| LTM Jun 2026 | $65.3M | +373.7% | -35.8% | 8.3% | |
| LTM Aug 2026 | -$7.38M | -2443.8% | — | 0.8% | |
| LTM Mar 2026 | -$10.89M | -115.5% | — | 10.9% | |
| LTM Mar 2026 | -$78.51M | +34.0% | — | 91.0% | |
| LTM Mar 2026 | -$162.78M | +80.2% | — | 101.7% | |
| LTM Sep 2026 | -$172.34M | -2543.7% | — | 27.7% | |
| Peer median (excluding MRVI) | -$9.13M | +19.6% | -17.6% | 15.3% | |
Competitors are the stored peer set for MRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 799.24M | 883M | 288.95M | 259.19M | 185.74M |
| Cost of Revenue | 140.56M | 168.96M | 148.74M | 150.88M | 152.35M |
| Gross Profit | 658.68M | 714.04M | 140.2M | 108.31M | 33.39M |
| Gross Margin | 82.4% | 80.9% | 48.5% | 41.8% | 18.0% |
| Research & Development | 15.22M | 18.37M | 17.28M | 19.22M | 23.33M |
| Selling, General & Admin | 100.06M | 129.26M | 151.39M | 161.77M | 171.47M |
| Operating Expenses | 104.03M | 139.83M | 171.85M | 343.93M | 40.13M |
| Depreciation & Amortization | 24.75M | 38.1M | 48.78M | 56.87M | 60.47M |
| EBITDA | 585.78M | 609.99M | 712.41M | (156.92M) | (147.51M) |
| EBITDA Margin | 73.3% | 69.1% | 246.6% | -60.5% | -79.4% |
| Operating Income | 554.65M | 574.22M | (31.65M) | (235.62M) | (6.74M) |
| Operating Margin | 69.4% | 65.0% | -11.0% | -90.9% | -3.6% |
| Interest Income | 0 | 2.34M | 27.73M | 27.4M | 23.95M |
| Interest Expense | 30.26M | 20.41M | 45.89M | 47.7M | 26.99M |
| Other Income / Expenses | (23.88M) | (22.74M) | 649.38M | (25.87M) | (228.24M) |
| Income Before Tax | 530.77M | 551.47M | 617.74M | (261.48M) | (234.97M) |
| Pre-Tax Margin | 66.4% | 62.5% | 213.8% | -100.9% | -126.5% |
| Income Tax Expense | 61.52M | 60.81M | 756.11M | (1.86M) | (4.21M) |
| Net Income | 182.04M | 220.21M | (119.03M) | (144.85M) | (130.77M) |
| Net Margin | 22.8% | 24.9% | -41.2% | -55.9% | -70.4% |
| EPS (Basic) | 1.59 | 1.67 | (0.90) | (1.05) | (0.91) |
| EPS (Diluted) | 1.56 | 1.67 | (0.90) | (1.05) | (0.91) |
| Weighted Avg Shares | 114.79M | 131.54M | 131.92M | 137.91M | 145.07M |
| Weighted Avg Shares (Diluted) | 121.97M | 131.7M | 131.92M | 137.91M | 145.07M |
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
Intrinsic Alpha fair value
Locked
Current Price
$7.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.